Background
Oxygen has the potential to elevate arterial partial pressure of carbon dioxide (PaCO
2) in patients with chronic obstructive pulmonary disease (COPD) [
1‐
5]. The incidence and magnitude is variable and it can occur in both stable and acute exacerbations of COPD [
1,
5]. Oxygen-induced hypercapnia is likely to be clinically important in the setting of acute exacerbations of COPD. A randomised-controlled trial (RCT) comparing high-concentration and titrated oxygen (to achieve arterial oxygen saturation (SpO
2) of 88 to 92%) in patients with an acute COPD exacerbation identified an over two-fold increase in mortality with high-concentration oxygen [
6]. Consequently oxygen therapy guidelines recommend titration of oxygen therapy within this SpO
2 range in patients with acute exacerbations of COPD, to avoid the risks of both hypoxaemia and hyperoxaemia [
2,
3].
A number of mechanisms have been proposed to explain how oxygen therapy increases PaCO
2. These include a reduction in hypoxic drive to breathe leading to decreased ventilation, and the release of hypoxic pulmonary vasoconstriction leading to worsening of ventilation-perfusion mismatch and increased alveolar deadspace [
5,
7]. RCTs report high-concentration oxygen therapy increases PaCO
2 in patients with asthma [
8], pneumonia [
9], and obesity [
10‐
12]. This suggests oxygen-induced hypercapnia might occur in a range of respiratory conditions with abnormal gas exchange and/or reduced ventilation with respiratory failure.
Neuromuscular disease and kyphoscoliosis can lead to hypoventilation and chronic respiratory failure; airflow obstruction and ventilation-perfusion mismatch are both features of bronchiectasis. As acute respiratory illnesses complicate both of these conditions and can result in hypoxia and the need for oxygen therapy, it is important to establish whether these patients are at risk of oxygen-induced hypercapnia. Two small sleep studies with a total of 17 participants [
13,
14] and one exercise study in 22 participants [
15] have been performed in patients with cystic fibrosis, which demonstrated average transcutaneous partial pressure of carbon dioxide (PtCO
2) increases between 4 [
15] and 7.5 mmHg [
13] during oxygen therapy compared to room air. In patients with neuromuscular disease data are limited to retrospective case examples [
16] and a retrospective case series in eight patients with a range of neuromuscular diseases [
17]. In the case series, low-flow oxygen (0.5-2 L/min) was associated with an elevation in PaCO
2 by an average 28 mmHg, however the measurements were made up to six days after oxygen therapy.
The purpose of our randomised cross-over trials was to investigate the effects of 50% oxygen compared to 21% oxygen in patients with stable neuromuscular disease or kyphoscoliosis and patients with stable bronchiectasis. To assess the applicability of the results to the clinical setting, we also studied stable COPD patients, matched by severity of airflow obstruction to the bronchiectasis patients. Our hypothesis was that oxygen therapy would increase PtCO2 in all three trials.
Methods
Overview
This series of three double-blind cross-over trials randomised patients to the order they received 50% oxygen (“oxygen” intervention) and medical grade air containing 21% oxygen (“air” intervention). The trials recruited 20 patients with neuromuscular disease or kyphoscoliosis (Neuromuscular/kyphoscoliosis Study), 24 patients with bronchiectasis (Bronchiectasis Study) and 24 patients with COPD (COPD Study). Each trial was prospectively registered on ANZCTR (ACTRN12615000970549, ACTRN12615000971538 and ACTRN12615001056583, respectively), and had Health and Disability Ethics Committee approval (see Online Supplement). Inclusion and exclusion criteria are presented in Table
1, including the criteria by which Bronchiectasis and COPD participants were matched by airflow obstruction severity.
Table 1Inclusion/Exclusion criteria
Inclusion criteria |
| Neuromuscular disease with ≥10% drop VC from sitting to lying or SNIP < 95% limit aand/or Kyphoscoliosis with an FVC < 65% predicted [ 18] b | Bronchiectasis as diagnosed by a doctor and confirmed with CT scan and/or Cystic fibrosis as diagnosed by a doctor | COPD, as diagnosed by a doctor |
Exclusion criteriac |
Study Baseline PtCO2 | ≥60 mmHg | ≥60 mmHg | ≥60 mmHg |
Age | < 14 years old | < 14 years old | < 16 years old |
Comorbidities | COPD Morbid obesityd | COPD Morbid obesityd | Bronchiectasis Morbid obesityd |
Spirometry | FEV1:FVC ratio ≤ 0.7, if participant is able to complete forced spirometry | | FEV1:FVC ratio > 0.7 Inability to match FEV1 percentage predicted with a Bronchiectasis study participante |
Other | | Infection with Burkholderia > 10 pack year smoking history | |
Potentially eligible patients were recruited through Hutt Valley Hospital, Wellington Regional Hospital and the Medical Research Institute of New Zealand (MRINZ) patient lists, as well as newsletters and posters. Participants attended a single study visit at the MRINZ. After confirming eligibility, study baseline PtCO2, heart rate, and SpO2 were recorded via a SenTec transcutaneous monitor (SenTec AG, Switzerland), and respiratory rate by investigator observation.
Participants were then fitted with a full-face positive airway pressure mask (Respironics), attached to a Douglas Bag (Hans Rudolph) via CO2SMO adapter (Novametrix Medical Systems), one-way T valve, respiratory filter (Microgard II, Carefusion), tubing and three-way tap, all connected in series. Participants breathed room air for at least 5 mins to adjust to breathing through the equipment, and then breathed the intervention gas for 30 min. After each intervention, the mask was removed and there was a 30 min observation period breathing room air.
Endpoint measurement
The primary endpoint was PtCO2 after 30 min.
Heart rate and PtCO2 were measured via SenTec. Respiratory rate, end tidal carbon dioxide (ETCO2), minute ventilation and dead space to tidal volume (VD/VT) were measured via CO2SMO (Model 8100), from which the tidal volume, volume of dead space, alveolar volume and alveolar minute ventilation were calculated (see Online Supplement for further detail regarding equipment methodology). Measurements were taken at T = 0 (following mask stabilisation and immediately prior to intervention), and at 10 min intervals during the intervention and observation periods. SpO2 on the SenTec display was covered during the intervention and washout periods to maintain investigator blinding. PtCO2 was monitored continuously; the intervention was stopped if values rose by ≥10 mmHg from T = 0.
The study statistician, who was not involved in study recruitment or visits, created computerised 1:1 randomisation sequences for each study. Randomisation codes were placed in sealed opaque envelopes and opened by the unblinded investigator following T = 0 measurements. The blinded investigator recorded all measurements from this point onwards.
Analyses
The primary analysis was a mixed linear model with fixed effects for the T = 0 measurements, intervention, and randomisation order, and a random effect for participants to take into account the cross-over design. For all measures an interaction term was tested first to see if there was any difference between the interventions that depended on the time of measurement. As secondary analyses for all outcomes, the differences between interventions at each measurement time were analysed by similarly structured models, with addition of the fixed effect of the time of measurement and a random effect for each participant using a spatial exponential in time repeated measures variance-covariance matrix to account for the cross-over design. The results of this model for PtCO
2 were compared between the COPD and Bronchiectasis study participants (as fixed effects), and were also adjusted for forced expiratory volume in one second (FEV
1) percentage predicted. Finally the difference in proportions of participants with a change in PtCO
2 of ≥ 4 mmHg and ≥ 10 mmHg from T = 0 were also estimated, as physiologically and clinically significant differences, respectively [
8,
9,
23]. All estimates of differences are shown as oxygen minus room air.
Software used
SAS version 9.4 was used.
Sample size
The intended sample size for each cross-over study was 24 based on 80% power and a type I error rate of 5%, to detect a difference of 2.4 mmHg. This is half the difference found in a study of participants with obesity hypoventilation syndrome which reported a mean (SD) paired difference of 5 (4) mmHg [
10].
Discussion
These randomised cross-over studies have shown that 50% oxygen for 30 min did not result in clinically significant increases in PtCO
2 at 30 min in patients with stable COPD, Bronchiectasis or Neuromuscular disease/Kyphoscoliosis. In the patients with stable COPD the mean PtCO
2 increase with high-concentration oxygen therapy was 1.3 mmHg; while this was statistically significant, the magnitude of the change is not of clinical significance. This is in contrast with the marked increases in PaCO
2 seen in the setting of acute exacerbations of COPD [
1,
5,
6]. This suggests that the results of all three studies in stable patients are unlikely to be generalisable to the use of oxygen therapy in the acute clinical setting.
To our knowledge there have been no RCTs investigating the effects of oxygen on PaCO
2 in acutely unwell patients with neuromuscular disease, kyphoscoliosis or bronchiectasis. However the risk of oxygen-induced hypercapnia has been well established through RCTs comparing high-concentration and titrated oxygen regimens in patients with acute COPD exacerbations [
6]. We undertook the current studies in patients with neuromuscular disease, kyphoscoliosis or bronchiectasis while stable, recognising that the results from stable patients in the laboratory setting may not translate to the clinical setting. We therefore conducted the study in COPD patients, as a comparator group in which clinically relevant oxygen-induced PaCO
2 elevations have been demonstrated [
1,
5,
6]. The study baseline SpO
2 and PtCO
2 values were comparable across all three studies, and FEV
1 percentage predicted matching between the COPD and Bronchiectasis patients ensured recruitment of patients with similar physiological impairment in terms of airflow obstruction. Contrary to findings in the acute setting [
1,
5,
6], oxygen administration did not result in a clinically significant change in PtCO
2 in the stable COPD patients, indicating that the study model was not an appropriate method to detect the potential for oxygen-induced hypercapnia in patients with neuromuscular disease, kyphoscoliosis or bronchiectasis in clinical practice.
A number of factors may explain the minimal PtCO
2 change in the COPD participants. Firstly, oxygen delivery was via a closed-circuit system, rather than standard masks used in clinical practice. This ensured precise fraction of inspired oxygen (FiO
2) administration and allowed deadspace and ventilation measurement. However, this method of delivery may have affected participant’s responses to the interventions, particularly as breathing through the study mask consistently resulted in a small increase in PtCO
2. Secondly, the studies were conducted in stable, rather than acutely unwell, patients. This allowed randomised cross-over trial design and meant that participants were more likely to tolerate study procedures. However, the physiological response to oxygen in stable patients may not translate to the acute setting. Previous studies investigating oxygen delivery to stable COPD patients have had variable results, ranging from no or small changes in mean PaCO
2 or PtCO
2 [
24‐
31] to marked increases [
23,
32‐
38]. Two studies have compared the effects of identical oxygen regimens in patients when having an acute exacerbation of their respiratory disease and when stable. Rudolf et al. found that an FiO
2 of up to 0.28 for 1 h increased PaCO
2 by 9, 15 and 31 mmHg compared with air in three patients with exacerbation of chronic respiratory failure [
39]. However, the same oxygen regimen did not alter PaCO
2 more than 3 mmHg when the same three patients were stable. Similarly, Aubier et al. found 30 min of oxygen via a mouthpiece increased average PaCO
2 by 10.1 mmHg in 12 patients during a COPD exacerbation [
25]. It increased by only 2.8 mmHg when the same patients were stable. The differences in response between acute and stable disease may relate to lower tidal volumes and/or a greater degree of hypoxic pulmonary vasoconstriction and ventilation/perfusion mismatch that occur in acute COPD exacerbation, which are further modified by oxygen therapy [
40,
41]. Additionally, acutely unwell patients are more likely to have lower SpO
2 levels and elevated PaCO
2 levels. While hypercapnia and hypoxaemia are not necessarily prerequisites for oxygen-induced hypercapnia [
38,
42], both have been associated with increased likelihood and magnitudes of oxygen-induced elevations in PaCO
2 [
10,
12,
23,
25,
33,
38]. In support of this, previous studies in stable COPD demonstrating significant oxygen-induced increases in PaCO
2 have had participants with lower baseline blood oxygen levels [
32,
34,
35,
38], and/or higher baseline PaCO
2 values [
23,
32‐
38] than the participants in the current three studies. Additionally, only one of the participants, from the COPD study, had a study baseline SpO
2 of 87%. All other participants had saturations ≥91%, meaning they were well above the SpO
2 level at which initiation of oxygen therapy is recommended in the acute clinical setting [
2,
3].
Oxygen therapy has previously been demonstrated to increase VD/VT [
10,
11,
23,
27,
35] and reduce ETCO
2 [
43]. However, caution is needed in interpreting the small increases in VD/VT and reductions in ETCO
2 during the oxygen intervention in the Bronchiectasis and COPD studies. These values were recorded by CO
2SMO and increased oxygen concentrations in the respiratory circuit could systematically decrease the displayed ETCO
2 while still keeping it within the manufacturer’s error range of up to 5% (User manual Oct 10, 1997). This decrease could explain the small changes in VD/VT and ETCO
2 observed.
There are a number of methodological issues relevant to interpretation of the study findings. Transcutaneous monitoring was used as a surrogate for PaCO
2 by arterial blood gas (ABG). ABGs and capillary blood gas sampling were not used to measure PaCO
2 during the interventions as they do not provide continuous measurement and cause discomfort. Additionally, ABG sampling carries risk of ischaemia. Our study outcome measures were change in PtCO
2 over time, which the SenTec has been demonstrated to accurately determine [
44,
45], with an estimate of bias for change in PtCO
2 of − 0.03 mmHg (95% CI − 0.44 to 0.38)
p = 0.89 when compared to arterialised blood gas values in COPD patients [
45]. Only 20 participants were recruited to the Neuromuscular/kyphoscoliosis study, however this did not affect the power to detect a difference in PtCO
2 between the interventions, given the SD was lower than that used for sample size calculation.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.